Protective effects of glucagon-like peptide-1 on beta cells: Preclinical data and clinical studies;Effetti protettivi del glucagon-like peptide-1 sulle beta-cellule: Dati preclinici e studi clinici

Giornale Italiano di Cardiologia

Volumn 12, Issue 12 SUPPL. 2, 2011, Pages

  Consoli, Agostino ^a   Di Biagio, Rosamaria ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Exenatide; Glucagon like peptide 1; Liraglutide; Obesity; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN GLARGINE; LIRAGLUTIDE;

APOPTOSIS; BLOOD GLUCOSE MONITORING; CELL PROTECTION; DOSE RESPONSE; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; IN VIVO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; RELIABILITY; REVIEW; TREATMENT DURATION;

EID: 84855832526     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: 10.1714/985.10684     Document Type: Review

References (26)

1. Consoli A. New therapeutic algorithm of type 2 diabetes: lights and shadows. J Endocrinol Invest 2011;34:65-8.
2. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004;53(Suppl 1):S119-S124. (Pubitemid 38168703)
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10. (Pubitemid 36042113)
4. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
5. Vilsboll T. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab 2009;11(Suppl 3):11-8.
6. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide-1 inhibits cell apoptosis and improves glucose responsiveness in freshly isolated human islets. Endocrinology 2003;144:5149-58. (Pubitemid 37476040)
7. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-408. (Pubitemid 35239574)
8. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270-6. (Pubitemid 30395416)
9. Natalicchio A, De Stefano F, Orlando MR, et al. Exendin-4 prevents c-Jun N-terminal protein kinase activation by tumor necrosis factor-alpha and inhibits TNF-alpha-induced apoptosis in insulin-secreting cells. Endocrinology 2010;151:2019-29.
10. Fan R, Li X, Gu X, Chan JC, Xu G. Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Diabetes Obes Metab 2010;12:815-24.
11. Cunha DA, Ladrière L, Ortis F, et al. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 2009;58:2851-62.
12. Sano H, Terasaki J, Mishiba Y, Imagawa A, Hanafusa T. Exendin-4, a glucagon-like peptide-1 receptor agonist, suppresses pancreatic beta-cell destruction induced by encephalomyocarditis virus. Biochem Biophys Res Commum 2011;404:756-61.
13. Merani S, Truong W, Emamaullee JA, Tosco C, Knudsen LB, Shapiro AM. Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice. Endocrinology 2008;149:4322-8.
14. Emamaullee JA, Merani S, Toso C, et al. Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology 2009;150:2145-52.
15. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002;283:E745-E752.
16. Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003;140:123-32. (Pubitemid 37175838)
17. Shimoda M, Kanda Y, Hamamoto S, et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 2011;54:1098-108.
18. Davies MJ, Kela R, Khunti K. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011;13:207-20.
19. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7. (Pubitemid 36993328)
20. Buse JB, Sesti G, Schmidt WE, et al.; Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010;33:1300-3.
21. Matthews D, Marre M, Le-Thi TD, et al. Liraglutide, a once-daily human GLP-1 analog, significantly improves beta-cell function in subjects with type 2 diabetes [abstract]. Diabetes 2008;57(Suppl 1):A150.
22. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100. (Pubitemid 40616618)
23. Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008;25:152-6. (Pubitemid 351293400)
24. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762-8.
25. Bunck MC, Cornér A, Eliasson B, et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2041-7.
26. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:348-56.